Condition

Lewy Body Dementia

Clinical trials and treatment information for Lewy Body Dementia, characterized by abnormal protein deposits in the brain.

5.7M
People Affected
150
Active Trials
171K
New Cases/Year
195K
Deaths/Year

Treatment Rankings

Ranked by evidence volume first. Medicine has spent centuries ranking things by vibes. This is an improvement.

1
Donepezil
70% Effectiveness• 85% Confidence• 60% Safety• 10 trials• 5.5K participants
MODERATE EvidenceExcellent ValueDose: 5-10 mg daily
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe

Time to Effect

4-12 weeks

Duration

lifetime

Response Rate

35%

Remission Rate

%

Number Needed to Treat (NNT)

8

Number Needed to Harm (NNH)

12

Common Side Effects:

Nausea: 15%
Diarrhea: 10%
Vomiting: 8%
Insomnia: 7%
Muscle cramps: 3%

Annual Cost of Care

Drug Cost

$75

Monitoring

$750

Side Effects

$150

Total Annual

$975

Cost-Effectiveness

EXCELLENT

QALYs Gained

0.1

ICER

$9,750/QALY

Cost per Responder

$2,786

Treatment Outcomes
Primary Outcomes
Cognitive Function (ADAS-Cog)28/70 points (ADAS-Cog)
-10.7% (-3 points)
Neuropsychiatric Symptoms (NPI Hallucinations)6/12 points (NPI Hallucinations)
-33.3% (-2 points)
Global Clinical Status (CDR-SB)5.5/18 points (CDR-SB)
-14.5% (-0.8 points)
Secondary Benefits
Overall Neuropsychiatric Symptoms (NPI Total)35/144 points (NPI Total)
-17.1% (-6 points)
Caregiver Burden (Zarit Burden Interview)30/88 points (ZBI)
-13.3% (-4 points)
Quality of Life (QOL-AD)30/52 points (QOL-AD)
+6.7% (+2 points)
Common Side Effects
Nausea
+15%
Diarrhea
+10%
Vomiting
+8%

Clinical Trial Phases:

Phase 4
2
Rivastigmine
70% Effectiveness• 85% Confidence• 60% Safety• 3 trials• 4.2K participants
MODERATE EvidenceExcellent ValueDose: Oral: 1.5-6 mg twice daily; Patch: 4.6 mg/24h, 9.5 mg/24h, 13.3 mg/24h
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe

Time to Effect

4-12 weeks

Duration

lifetime

Response Rate

35%

Remission Rate

%

Number Needed to Treat (NNT)

8

Number Needed to Harm (NNH)

13

Common Side Effects:

Nausea: 18%
Vomiting: 10%
Diarrhea: 10%
Dizziness: 8%
Application site reactions (patch): 15%

Annual Cost of Care

Drug Cost

$150

Monitoring

$750

Side Effects

$150

Total Annual

$1,050

Cost-Effectiveness

EXCELLENT

QALYs Gained

0.1

ICER

$10,500/QALY

Cost per Responder

$3,000

Treatment Outcomes
Primary Outcomes
ADAS-Cog total score28 points (range 0-70)
-11.4% (-3.2 points)
NPI total score35 points (range 0-144)
-21.4% (-7.5 points)
ADCS-ADL score60 points (range 0-78)
+4.2% (+2.5 points)
Secondary Benefits
NPI-Hallucinations domain score5 points (range 0-12)
-36% (-1.8 points)
CGI-I (Clinician's Global Impression - Improvement) mean scoreImplicit 4 (No Change) on 7-point scale
-16.7% (-0.5 points)
Common Side Effects
Nausea
+18%
Vomiting
+10%
Diarrhea
+10%

Clinical Trial Phases:

Phase 4
3
Physical and Occupational Therapy
75% Effectiveness• 90% Confidence• 95% Safety• 1 trials• 2.5K participants
MODERATE EvidenceExcellent ValueDose: 30-60 minutes, 2-3 times per week, plus daily home exercise
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
95
DangerousModerateSafe

Time to Effect

Immediate with progressive improvement over weeks to months

Duration

ongoing/lifetime

Response Rate

75%

Remission Rate

%

Common Side Effects:

Muscle soreness: 15%
Fatigue: 8%
Minor injury (rare with supervision): 0.5%

Annual Cost of Care

Drug Cost

$0

Monitoring

$1,000

Side Effects

$0

Total Annual

$1,000

Cost-Effectiveness

EXCELLENT

QALYs Gained

0.2

ICER

$25,500/QALY

Cost per Responder

$6,800

Treatment Outcomes
Primary Outcomes
Motor UPDRS Part III Score35 points (0-108 scale)
-12% (-4.2 points)
Berg Balance Scale (BBS) Score40 points (0-56 scale)
+12.5% (+5 points)
Functional Independence Measure (FIM) Total Score80 points (18-126 scale)
+12.5% (+10 points)
Timed Up and Go (TUG) Test15 seconds
-13.3% (-2 seconds)
Secondary Benefits
Parkinson's Disease Questionnaire (PDQ-39) Summary Index Score45 points (0-100 scale)
-15% (-6.75 points)
Falls per Month2 falls/month
-50% (-1 fall/month)
Zarit Burden Interview (ZBI) Score30 points (0-88 scale)
-10% (-3 points)
Common Side Effects
Muscle soreness
+15%
Fatigue
+8%
Minor injury (rare with supervision)
+0.5%
4
Pimavanserin
65% Effectiveness• 80% Confidence• 55% Safety• 2 trials• 2.2K participants
MODERATE EvidencePoor ValueDose: 34 mg once daily
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe

Time to Effect

2-4 weeks

Duration

lifetime

Response Rate

45%

Remission Rate

%

Number Needed to Treat (NNT)

8

Number Needed to Harm (NNH)

18

Common Side Effects:

Peripheral edema: 8%
Nausea: 7%
Confusion: 4%
QT prolongation: 0.5%

Annual Cost of Care

Drug Cost

$45,000

Monitoring

$750

Side Effects

$300

Total Annual

$46,050

Cost-Effectiveness

POOR

QALYs Gained

0.2

ICER

$230,250/QALY

Cost per Responder

$102,333

Treatment Outcomes
Primary Outcomes
NPI-NH Psychosis Score8/24 (NPI-NH Psychosis domain)
-25% (-2.0 points)
NPI-NH Caregiver Distress (Psychosis)15/40 (NPI-NH Caregiver Distress related to psychosis)
-18% (-2.7 points)
MDS-UPDRS Part III Score35/108 (MDS-UPDRS Part III)
-1.5% (-0.5 points)
Secondary Benefits
CGI-S Score5/7 (CGI-S, Markedly Ill)
-20% (-1.0 points)
NPI-NH Sleep & Nighttime Behaviors Score6/12 (NPI-NH Sleep domain)
-15% (-0.9 points)
ADCS-ADL Score45/78 (ADCS-ADL)
+2% (+0.9 points)
Common Side Effects
Peripheral edema
+8%
Nausea
+7%
Confusion
+4%

Clinical Trial Phases:

Phase 4
5
Carbidopa/Levodopa
65% Effectiveness• 80% Confidence• 55% Safety• 55 trials• 10.5K participants
MODERATE EvidenceExcellent ValueDose: Typically 25/100 mg 3-4 times daily, titrated
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe

Time to Effect

Days to weeks

Duration

lifetime

Response Rate

30%

Remission Rate

%

Number Needed to Treat (NNT)

4

Number Needed to Harm (NNH)

7

Common Side Effects:

Nausea: 15%
Orthostatic hypotension: 15%
Hallucinations/Delusions: 20%
Dyskinesia: 12%
Dizziness: 8%

Annual Cost of Care

Drug Cost

$100

Monitoring

$750

Side Effects

$350

Total Annual

$1,200

Cost-Effectiveness

EXCELLENT

QALYs Gained

0.07

ICER

$17,143/QALY

Cost per Responder

$4,000

Treatment Outcomes
Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+30%
Common Side Effects
Nausea
+15%
Orthostatic hypotension
+15%
Hallucinations/Delusions
+20%

Clinical Trial Phases:

Phase 4
6
Memantine
55% Effectiveness• 70% Confidence• 70% Safety• 4 trials• 1.6K participants
MODERATE EvidenceExcellent ValueDose: 5-20 mg daily, titrated
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe

Time to Effect

2-4 weeks

Duration

lifetime

Response Rate

25%

Remission Rate

%

Number Needed to Treat (NNT)

12

Number Needed to Harm (NNH)

50

Common Side Effects:

Dizziness: 8%
Headache: 7%
Confusion: 4%
Constipation: 4%

Annual Cost of Care

Drug Cost

$75

Monitoring

$750

Side Effects

$75

Total Annual

$900

Cost-Effectiveness

EXCELLENT

QALYs Gained

0.07

ICER

$12,857/QALY

Cost per Responder

$3,600

Treatment Outcomes
Primary Outcomes
Change of Mini Mental State Examination (MMSE) Test Result
0%
Change of Adenbrooke's Cognitive Examination (ACE) Test Result
0%
Percentage of Participants With a Serum Concentration Within the Therapeutic Reference Range (TRR) at 12 Month Follow-up Visit.23 Participants
+13% (+3.0 Participants)
Level of Compliance to Treatment48 Participants
-98% (-47.0 Participants)
Secondary Benefits
Change of Clinical Global Impression (CGI) Score Result
0%
Change in Geriatric Depression Scale (GDS) Symptoms Score
0%
Change of Disability Assessment for Dementia (DAD) Score Result
0%
Common Side Effects
Dizziness
+8%
Headache
+7%
Confusion
+4%

Clinical Trial Phases:

Phase 4